The Living Biobank consists of a rapidly growing collection of organoids from patients with various forms of cancer (colon, prostrate, lung, pancreas) and cystic fibrosis. The organoids are characterized by genome sequencing, expression profiling and sensitivity to known drugs to establish a database linking genetic and transcriptional information to drug responsiveness.
Using the Living Biobank, the HUB explores novel therapeutic strategies, including responsiveness to drug combinations, to develop rules for patient stratification based on drug sensitivity in vitro. Connecting genomic heterogeneity and gene function to in vitro drug responsiveness will lead to the development of a road map for improved treatment strategies.
See more at the HUB Biobank Database